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Abstract
Background: There is an unmet need for novel treatments, such as drugs or vaccines, adjunctive to or
replacing a burdensome life-long gluten-free diet for coeliac disease. The gold standard for successful
treatment is a healed small intestinal mucosa, and therefore, the outcome measures in proof-of-concept
studies should be based on evaluation of small intestine biopsies. We here evaluated morphometric,
immunohistochemical and messenger RNA (mRNA) expression changes in coeliac disease patients challenged
with gluten using PAXgene fixed paraffin-embedded biopsies.
Methods: Fifteen coeliac disease patients were challenged with 4 g of gluten per day for 10 weeks and 24 non-coeliac
patients served as disease controls. A wide array of histological and immunohistochemical staining and mRNA-based
gene expression tests (RT-qPCR and RNAseq) were carried out.
Results: Digital quantitative villous height: crypt depth ratio (VH: CrD) measurements revealed significant duodenal
mucosal deterioration in all coeliac disease patients on gluten challenge. In contrast, the Marsh-Oberhuber class worsened
in only 80% of coeliac patients. Measuring the intraepithelial CD3+ T-lymphocyte and lamina propria CD138+ plasma cell
densities simultaneously proved to be a meaningful new measure of inflammation. Stainings for γδ T cells and IgA
deposits, where previously frozen samples have been needed, were successful in PAXgene fixed paraffin-embedded
samples. Messenger RNA extraction from the same paraffin-embedded biopsy block was successful and allowed large-scale
qRT-PCR and RNAseq analyses for gene expression. Molecular morphometry, using the mRNA expression ratio of villous
epithelium-specific gene APOA4 to crypt proliferation gene Ki67, showed a similar significant distinction between paired
baseline and post-gluten challenge biopsies as quantitative histomorphometry.
(Continued on next page)
© The Author(s). 2019 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
* Correspondence: jorma.isola@tuni.fi
5Laboratory of Cancer Biology, Faculty of Medicine and Health Technology,
Tampere University, Tampere, Finland
6Jilab Inc., Tampere, Finland
Full list of author information is available at the end of the article
Taavela et al. BMC Gastroenterology          (2019) 19:189 
https://doi.org/10.1186/s12876-019-1089-7
(Continued from previous page)
Conclusion: Rigorous digitally measured histologic and molecular markers suitable for gluten challenge studies can be
obtained from a single paraffin-embedded biopsy specimen. Molecular morphometry seems to be a promising new tool
that can be used in situations where assessing duodenal mucosal health is of paramount importance. In addition, the
diagnostically valuable IgA deposits were now stained in paraffin-embedded specimens making them more accessible in
routine clinics.
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Background
Coeliac disease is an autoimmune disorder in which
dietary gluten causes a gradually developing villous at-
rophy and crypt hyperplasia in small intestine mucosa
[1]. Patients may present with severe gastrointestinal
symptoms, extraintestinal manifestations such as
dermatitis herpetiformis, or be asymptomatic but diag-
nosed by at-risk group screening [2]. Currently, the
only therapeutic option is a life-long, strict gluten-free
diet, which is burdensome and limits the normal day-
to-day life [3]. Gluten is abundant in everyday diets,
and gluten contamination of otherwise gluten-free
foods is difficult to avoid [4]. In fact, 20–50% of
treated coeliac patients report gastrointestinal symp-
toms [5]. Hence, coeliac patients have expressed a de-
sire to use novel drugs or vaccines as adjunctive or
even alternative treatments for coeliac disease [6].
Mucosal healing is the ultimate goal in coeliac disease
dietary treatment, but this is often not achieved, as
reviewed by Ilus et al. [7].
Gluten challenge studies are a rising entity for undergo-
ing and upcoming drug and vaccine trials for coeliac dis-
ease [8]. Normal food contains approximately 10–20 g of
gluten per day, and a daily dose of only 1–3 grams [9, 10]
or even 50 micrograms [11] of gluten can induce measur-
able histological changes in gluten challenge studies. The
mucosal damage depends on the dose and duration of the
gluten challenge [9, 10]. Patient-related outcomes (PROs)
can also be used as a disease severity indicator [12]; how-
ever, the symptoms of an individual patient may not re-
flect the mucosal status during the relatively short gluten
challenge [13, 14]. Hence, histological analyses have been
used and are considered necessary in clinical phase II
proof-of-concept drug trials to demonstrate objective
morphological and inflammatory gluten-induced change
in coeliac disease patients [15].
In gluten challenge studies, the technical quality of the
histological biopsy samples must be rigorously moni-
tored and ensured to produce reliable results, as there
are several pitfalls in obtaining the biopsy, orientating
the biopsy section and evaluating the section [16–18].
Conventionally, duodenal biopsies are fixed with forma-
lin and embedded in paraffin (FFPE), which allow the
analysis of duodenal morphology, density of intraepithe-
lial lymphocytes (IELs) and proteins through label-free
quantitative mass spectrometry [19], but many immuno-
histochemical markers and messenger RNAs (mRNAs)
that would provide detailed molecular data cannot be
analysed from the same biopsy specimens when formalin
is used as a fixative. Similarly, samples stored in RNA-
preserving reagents, such as RNAlater, cannot be used
for histology or immunohistochemistry [20]. Frozen sec-
tions can be used for both, but rapid deep-freezing and
transportation of the biopsies is difficult to arrange in
multicentre clinical drug trials. Moreover, high-quality
frozen sectioning of mucosal biopsies is technically chal-
lenging. The new PAXgene molecular fixative allows
histological, immunohistochemical, and mRNA studies
[21, 22], and thus, it may enable a much wider array of
histological and biological outcome measures from sin-
gle duodenal biopsies that would give important infor-
mation, especially in the new coeliac disease drug trials.
Hence, we studied here quantitative histological mea-
surements, multiple immunohistochemical markers and
RNA markers with PAXgene fixative in a gluten chal-
lenge setting in coeliac disease patients.
Methods
Patients and biopsies
Altogether, 15 adult patients with previously diagnosed
coeliac disease were recruited for a gluten challenge
study. Coeliac disease diagnosis was ensured in all
coeliac disease patients from patient records before glu-
ten challenge. This comprised positive coeliac disease
autoantibody tests and the characteristic histological
changes of villous atrophy and crypt hyperplasia in the
duodenal biopsy. All celiac disease patients had been on
a gluten-free diet for at least 1 year. The patients were
subjected to a gluten challenge of 4 g of gluten per day.
Biopsies were taken before the gluten challenge, and the
same study subjects were biopsied again 10 weeks after
the beginning of the gluten challenge. Twenty-four non-
coeliac disease control patients undergoing clinically in-
dicated upper gastrointestinal endoscopies were invited
to participate. For these patients, endoscopy was per-
formed due to unexplained abdominal symptoms,
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dyspepsia or symptoms of gastroesophageal reflux with-
out suspicion of coeliac disease. Coeliac disease was ex-
cluded in the control group by normal histopathology
findings in routine pathologic examination of duodenal
biopsies. They were also negative for serum coeliac dis-
ease autoantibodies.
Six biopsy samples were taken from the distal duode-
num and placed in a multi-compartment tissue cassette,
which was immersed in PAXgene fixative for 1–4 h and
transferred to the proprietary storage solution in PAX-
gene dual-chamber fixative containers (Qiagen #765112,
Venlo, Netherlands). Biopsies were stored at + 4 °C and
transferred to the central pathology laboratory at ambi-
ent temperature. Of the 24 non-coeliac patients, 15 pa-
tients’ biopsies were fixed with routine formalin fixative,
five with PAXgene fixative and four subjects had both
formalin and PAXgene fixed specimens.
Biopsy processing and staining
PAXgene-fixed samples were processed for paraffin
block embedding (PaxFPE) using a standard formalin-
free paraffin-infiltration protocol. Each biopsy was em-
bedded in a separate paraffin block under a dissection
microscope and aimed for a cutting plane perpendicular
to the mucosal lumen surface to orientate the specimens
correctly [16]. To measure villous height (VH), crypt
depth (CrD), and their ratio (VH: CrD), the slides were
stained with haematoxylin and eosin.
Immunohistochemical staining was carried out, and
lymphocytes were stained separately for CD3, CD4,
CD8, CD19, CD138, CD163, FOXP3, Ki67, CyclinB1 and
γδ. Additionally, double immunofluorescence of CD3/
CD8 lymphocytes and IgA deposits, i.e., visualizing duo-
denal mucosal IgA targeting extracellular TG2, was car-
ried out [23]. The staining procedures are described in
detail in Additional file 1.
Digital histomorphometry
All slides were scanned as whole-slide images using a
SlideStrider scanner at a resolution of 0.28 μm per pixel
(Jilab Inc., Tampere, Finland). Images were stored as
JPEG2000 files in the image server and viewed over the
internet with web-based client software developed for
this study (Celiac Slide Viewer). The sections were ana-
lysed according to our standard operating procedure
[16]. The small intestinal mucosal VH and CrD were
evaluated from at least three separate villous-crypt units,
and the result was given as the average of the ratios. VH
and CrD were measured digitally by drawing polylines
(Fig. 1a). Two academic observers (JT, AP) analysed all
slides independently and were unaware of the clinical
data or laboratory findings of the patients. A crucial step
in the procedure was that an experienced evaluator, be-
sides producing results with acceptable interobserver
and intraobserver morphometric variation, identified
cases that had inadequate sample material and/or poor
biopsy orientation, where measurements of villous-crypt
units are not reliable [16]. In the case of poor orientation
that resulted in tangential cuttings, the evaluator asked
Fig. 1 Examples of digital measuring in coeliac disease biopsy specimens. Villous height, crypt depth and villous height: crypt depth ratio
measurements in haematoxylin and eosin–stained specimens (a), CD3+ intraepithelial lymphocyte density count per enterocyte (b) and γδ+
intraepithelial lymphocyte staining in PAXgene-fixed specimens (c). Measurements were performed with Celiac Slide Viewer
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for recuttings until reliable morphological readouts
could be obtained.
CD3+ and γδ+ IELs were measured within the epithe-
lium of at least 300 enterocytes using the Auto-IEL tool
of Celiac Slide Viewer (Fig. 1b and c), and the result was
given as IEL density expressed per 100 enterocytes
(ECs). In IEL measurements, the results are independent
of biopsy orientation, and re-cutting of specimens is not
needed [16]. CD138+ plasma cells in the lamina propria
were enumerated automatically and adjusted to the
measurement area with ImmunoRatio2 software, which
is part of the Celiac Slide Viewer.
Messenger RNA analyses
Total RNA was extracted from PAXgene-fixed and
formalin-fixed specimens (30 to 50 unmounted tissue
sections of a single biopsy) according to the manufac-
turer’s instructions. Quantitative real-time PCR using
RT [2] Profiler PCR arrays and RNAseq were carried out
and the data were analysed. Methods are described in
detail in the Additional file 1.
Statistics
Quantitative data are expressed as the means, percent-
ages and ranges. The two-tailed pairwise Mann-Whitney
U test and the Kruskal-Wallis test were used to compare
the differences between the groups. All statistical testing
was performed using Predictive Analytics Software Sta-
tistics (PASW) version 18 (IBM, USA).
Results
Mucosal architecture assessments
VH, CrD and their ratio were similar between disease con-
trol patients and coeliac disease patients on a gluten-free
diet (Fig. 2). In coeliac disease patients, a significant change
was seen between baseline and post gluten challenge values
in PaxFPE samples (p < 0.001, Fig. 2). The PaxFPE samples
of non-coeliac disease controls were readable in eight out of
nine samples, and the median VH, CrD and VH: CrD were
401 μm (284–521), 177 μm (range 115–213) and 2.3 (range
1.9–2.5), respectively; in coeliac disease patients on GFD,
the values were 369 (range 327–406), 172 (range 126–203)
and 2.2 (range 1.7–3.2; n = 15/15); and after the gluten chal-
lenge, they were 202 μm (range 96–425), 255 μm (range
158–392) and 0.9 (range 0.2–2.6; n = 15/15). In FFPE sam-
ples of non-coeliac disease control patients, the VH, CrD
and VH: CrD were 533 μm (range 448–625), 196 μm (165–
258) and 2.7 (range 2.0–3.2; n = 19/19), respectively, show-
ing significantly higher VH (p < 0.001) and VH: CrD (p =
0.0024) than in PaxFPE (Fig. 3). In pairwise analysis (n = 4)
of FFPE and PaxFPE specimens, the median VH, CrD and
VH: CrD were 518 μm (448–591), 200 μm (164–258) and
2.6 (2.3–2.8), respectively; in PaxFPE the values were
401 μm (343–488), 176 μm (143–212) and 2.3 (1.9–2.5).
Mucosal T- and B-lymphocytes
Intraepithelial CD3+ and γδ+ IEL densities were signifi-
cantly elevated (p = 0.002; p = 0.02) in the coeliac disease
patients on GFD with a mean of 32.1 per 100 ECs (range
18–43) and 6.9 per 100 ECs (range 1–14) compared to
non-coeliac disease control patients 18.7 per 100 ECs
(range 8–34) and 2.3 per 100 ECs (range 0–13), respect-
ively. In the gluten challenge, the CD3+ and γδ+ IEL
densities increased to a mean of 60.9 per 100 ECs (range
49–88) and a mean of 12.6 per 100 ECs (range 3–34;
Fig. 4) and were significant (p < 0.001, p = 0.007).
To explore the role of B-cell lineage, we stained the
study material for CD138, which specifically showed
plasma cells in the lamina propria (Fig. 5). The CD138+
lymphocytes were elevated significantly in the coeliac
disease patients on GFD, with a mean of 3580 per mm2
of lamina propria (range 2320–4450), compared to dis-
ease control patients, who had a mean of 2390 per mm2
(p < 0.001; range 1650–3140). After gluten challenge, a
significant increase to a mean of 5013 per mm2 of lam-
ina propria was observed (p < 0.001; range 3709–6108).
Fig. 2 Mucosal morphology in gluten challenge. The measurement of villous height, crypt depth and villous height: crypt depth ratio in non-
coeliac disease control patients, in coeliac disease patients on a gluten-free diet (GFD) before gluten challenge and then in coeliac disease
patients after the gluten challenge. There was no significant change in non-coeliac disease control patients or coeliac disease on a gluten-free
diet in any parameter, but as expected, significant changes were seen between the samples taken before and after the gluten challenge in
coeliac disease patients
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Conversion of villous height and crypt depth
measurements to Marsh-Oberhuber classification
Conversion from the continuous injury parameters VH:
CrD and IEL to the grouped Marsh-Oberhuber injury
classification grading system (classes 0, 1, 2, 3a, 3b, 3c)
can be achieved using the conversion table provided by
Adelmann et al. [24] However, based on the observed
shrinkage of villi in PAXgene fixative and the conse-
quent lower VH: CrD values in PaxFPE samples, we re-
formulated the conversion table to match the results ob-
tained with PaxFPE biopsies (Additional file 2: Table
S1). With this conversion table, we observed a clinically
significant Marsh score change (2 or more classes) in
80% of cases after gluten challenge (Table 1) [25]. For
comparison, when using the continuous injury variable
VH: CrD ratio as the outcome, clinically significant
worsening (0.4 units or more) [16] was evident in all
coeliac disease patients.
Immunofluorescence assays
The staining of IgA deposits using double immuno-
fluorescence staining of IgA and transglutaminase 2
(Additional file 3: Figure S1) was successful with
PAXgene, which so far has been possible only on fro-
zen sections. Also, the staining reactions were strong
in dual-colour indirect immunofluorescence staining
of CD3+CD8− IELs (Additional file 3: Figure S1) and
in an immunohistochemical panel (CD4, CD8, CD19,
CD163, and FOXP3) consisting of markers known to
be relevant for the pathogenesis of coeliac disease
(Additional file 4: Figure S2). Formalin fixation pro-
vides the same staining possibilities as this immuno-
histochemical panel but lacks the possibility to stain
IgA deposits and γδ+ T cells.
Gene expression profiling
The main technical advantage of the PaxFPE technology is
the possibility to extract RNA for molecular gene expres-
sion studies. For this, we extracted RNA from the same
paraffin blocks that were first used for histological sections
(see Additional file 1). Despite the small amount of tissue
used for RNA extraction, 3 to 14 micrograms RNA was
obtained. The quality of RNA, as estimated by the RQN
values, varied from 2.1 to 5.6, which is typical for the RNA
obtained from intestinal tissues. Somewhat compromised
RQN values notwithstanding, we were able to perform
gene expression analyses. To exemplify this, we analysed
the mRNA levels of two genes whose expression is corre-
lated with coeliac disease mucosal damage, namely,
APOA4 [26] and Ki67 [27], by RT-qPCR and RNAseq.
Fig. 3 Comparison of mucosal morphology between formalin and PAXgene fixed specimens. Villous height, crypt depth and villous height:crypt
depth ratio measurements in routine formalin-fixed biopsies and in PAXgene-fixed biopsies. The villi were significantly lower in PAXgene-fixed
samples, but crypts were unaffected. There was also a trend towards lower villous height:crypt depth ratio in PAXgene-fixed samples
Fig. 4 Mucosal inflammation in gluten challenge. CD3+ and γδ+ intraepithelial lymphocyte (IEL) density in non-coeliac disease control patients, in
coeliac disease patients on a gluten-free diet (GFD) and in coeliac disease patients after gluten challenge
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For comparison, we tested the possibility of RNA ana-
lysis also with traditional formalin-fixed small bowel bi-
opsies from three patients (see Additional file 1). The
RNA yield from these samples was very low ranging
from 0.092 to 0.12 micrograms. Understandably, RQN
values could not be defined and RT-qPCR analyses did
not give any signal in these specimens. This finding is in
agreement with previous studies [20].
In RNAseq, the total number of reads was 196,558,
237, and there were 4,820,392 reads on average per sam-
ple. The median of detected genes across all 36 samples
was 19,863 (standard deviation 1910). The mean reads
per unique molecular identifiers (UMI) was 4.12 (stand-
ard deviation 0.36). In 89% of samples, the number of
detected genes was over 17,000. The reads per UMI was
over 3 in 97% of samples.
Figure 6a and b show the villous epithelial staining of
APOA4 and the crypt epithelial staining of Ki67. Fig-
ure 6c and d show the RNAseq-extracted mRNA levels
of APOA4 and Ki67 in disease controls and in coeliac
disease patients before and after gluten challenge, as in-
dividual plots and group means. The ratio of APOA4 to
Ki67 encompasses both the mRNA levels of villi
(APOA4) and crypts (Ki67) (Fig. 6e). Hence, these re-
sults present the gluten-induced changes that occur in
molecular VH (APO4), CrD (Ki67) and VH: CrD
(APOA4/Ki67) alongside the architectural mucosal
changes in coeliac disease. Figure 6f further demon-
strates the changes between the APOA4/Ki67 mRNA ra-
tio and the histological Marsh-Oberhuber classes of
biopsy specimens. Additionally, the correlation coeffi-
cient between the APOA4:Ki67 mRNA ratio and the
morphometrical VH: CrD was good, at 0.634 (p < 0.001),
and APOA4:Ki67 mRNA ratio correlated well with the
IEL density (− 0.575, p < 0.001). The correlation coeffi-
cient of APOA4 between the two methods, RT-PCR and
RNAseq, was excellent (0.95), indicating that the RNA
analyses are highly reproducible.
Discussion
In coeliac disease, the mucosal architectural injury and
intra-epithelial inflammation induced by the ingested
gluten are both biological continuums, which can be
measured morphometrically [9, 16]. However, in the
clinic, the status of mucosa is most often depicted
with categorical classifications, such as the Marsh-
Oberhuber classification, where the injury continuum
is grouped in a non-biological way into 6 classes [28].
This is valid when diagnosing coeliac disease, but for
gluten challenge studies, which are used in drug or
vaccine trials, more precise measurements are needed.
In gluten challenges, small but significant mucosal
changes must be observed in well-treated coeliac dis-
ease patients who have ingested low or moderate
Fig. 5 CD138+ lymphocytes in gluten challenge. CD138+ lymphocytes in lamina propria stained from PAXgene-fixed duodenal biopsies before (a)
and after the gluten challenge (b) in a coeliac disease patient. The CD138+ lymphocyte density was increased in coeliac disease patients on
gluten-free diet (GFD) compared with non-coeliac disease control patients; the CD138+ lymphocyte density also increased significantly after the
gluten challenge in coeliac disease patients (c)
Table 1 The change in duodenum estimated before and after
the gluten challenge with the Marsh-Oberhuber
classification.change in duodenum estimated before and after
the gluten challenge with the Marsh-Oberhuber classification
Marsh class change Number of study subjects (%)
No change 1 (7%)
Change by one classa 2 (13%)
Change by two classesb 8 (53%)
Change by three classesc 4 (27%)
aFrom M1 to M2, M2 to M3a, M3a to M3b, or M3b to M3c
bFrom M1 to M3a, M3a to M3c, or M2 to M3b
cFrom M1 to M3b, M2 to M3c, or M1 to M3c
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amounts of gluten for a short period of time. For this
purpose, quantitative morphometric measurements
such as mucosal architectural changes (VH: CrD) and
inflammation (IEL density) are essential [15]. Indeed,
clinically significant mucosal changes are seen within
one single Marsh-Oberhuber class [10, 16]. In this
study, a conversion table was created in which duo-
denal mucosal morphometric measurements could be
changed into Marsh-Oberhuber classes in PAXgene-
fixed samples. It was evident with this conversion
table that categorical classification would have missed
20% of patients showing evident mucosal change in
VH: CrD measurements. This finding agrees with pre-
vious studies showing poor performance of categorical
classifications in gluten challenge studies [9, 11, 16].
Measurement of IELs provides another continuous,
quantifiable parameter that is not fully considered in
any of the categorical classifications despite its
importance as an early marker of inflammation in
short gluten challenges [9].
Frozen specimens have been used to stain the γδ +
IELs and IgA deposits, which have been used widely
as markers for latent, i.e., early-onset, coeliac disease
[23, 29–32]. The rapid freezing of duodenal biopsies
makes it difficult to arrange them such that they are
assessable in remote clinical centres, and the trans-
portation of deep-frozen specimens is burdensome as
it requires special packaging and shipping. Intri-
guingly, γδ+ IELs and IgA deposit stainings were
reproduced with PaxFPE biopsy blocks but not in
formalin-fixed samples. This offers a significant new
option for clinical routine and potentially for forth-
coming coeliac drug trials, as the need for biopsy
freezing has been the main hindrance to the wider
use of IgA deposit studies in coeliac disease despite
its almost 100% accuracy [32].
Fig. 6 Molecular morphometry in gluten challenge. Immunohistochemical stainings of APOA4 (a) and Ki67 (b) in PAXgene fixative and the mRNA
levels of these genes in disease controls (DS) and before and after the gluten challenge. In pairwise analysis of each patient, the expression of the
villous epithelium gene APOA4 decreased significantly after gluten challenge (c), whereas crypt cell proliferation, as indicated by Ki67 messenger
RNA, increased significantly (d). The ratio of these two genes appeared to be the most prominent marker (e). APOA4 and Ki67 ratio and Marsh-
Oberhuber classification, which was obtained via the conversion table (presented in Additional file 2: Table S1) from the villous height:crypt depth
ratio and intraepithelial lymphocyte count, had a significant correlation, thus displaying the clinical link between these mRNA markers and
mucosal injury (f). †Disease controls, DS; ‡ one sample was out of the measurement scale, with a value of 257
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Another promising marker for measuring coeliac dis-
ease outcome is quantitation of the antibody-producing
plasma cells in the lamina propria [33]. Interestingly, in
a new article by Høydahl et al. the plasma cells are sug-
gested to be the most prevalent antigen presenting cell
in celiac disease and a potential target for treatment
[34]. In our study, the number of CD138+ plasma cells
was somewhat elevated in coeliac disease patients on a
strict gluten-free diet, but it increased highly significantly
upon a moderate and short-term gluten challenge. With
digital image analysis, it was feasible to measure the
number of CD138+ cells per mm2 of lamina propria,
thereby providing an observer-independent measure of
gluten-dependent coeliac disease activity. Measuring
IELs and lamina propria B cell density responses simul-
taneously could constitute a new duodenal inflammation
outcome marker in gluten challenge studies. It remains
to be seen whether quantitation of TG2-producing
plasma cells will give added value in short-term gluten
challenge studies [35].
There are several pitfalls in the histological meas-
urement of biopsies [16, 17]. The agreement between
local and central pathologist in Marsh-Oberhuber
classes is only 42%, and even the diagnoses differed
(normal vs coeliac disease) in 7% of patients in a
large European multicentre study [18]. Thus, object-
ive quantitative measurements using digital histo-
morphometric tools and new immunohistochemistry
and/or mRNA analyses could provide significant help
to assess the degree of damage in the small bowel
mucosa. In our mRNA analyses, we found that suffi-
cient material could be harvested from PAXgene-
fixed biopsy blocks. Additionally, PAXgene requires
less biopsy material than the combination of routine
formalin samples and RNAlater assessments. This
will make endoscopy easier and faster and, in
addition, is a simpler method to store and ship the
samples as only one biopsy is needed to acquire
both histology and mRNA results. Separate biopsy
specimens may also have considerable variation in
mucosal morphology and inflammation for which the
single specimen analysis provides consistency and
removes any biopsy-based discrepancy in results. As
an example of the potential use of molecular morph-
ology in duodenal biopsies, we selected the mRNA
of a known villous gene marker, APOA4, and a crypt
proliferation marker, Ki67, for further study. These
markers, and especially the villous:crypt ratio of
these two parameters, APOA4/Ki67, appeared to
measure coeliac disease activity well in the gluten
challenge. APOA4 and Ki67 ratio had a high correl-
ation to mucosal VH: CrD and performed well in
the comparison to Marsh-Oberhuber classes (Fig. 6f).
Therefore, the use of RNAseq data could be
especially valuable to ensure more reliable results
when used in combination with routine morpho-
logical biopsy assessment in gluten challenge set-
tings. A more detailed bioinformatics-based analysis
of the mRNA levels of the ~ 19,000 genes analysed
in one RNAseq run will be reported elsewhere (Viiri
et al., manuscript in preparation).
Conclusions
Significant gluten-induced morphological (VH: CrD)
and inflammatory (CD3+ IELs and CD138+ lamina
propria plasma cells) changes are measurable in gluten
challenge studies using digitally measured quantitative
variables. With PAXgene fixative it is also possible to
acquire a wide array of immunohistochemical stain-
ings and quantitative analyses of mRNA from single
paraffin-embedded biopsy specimens. In particular,
the possibility to stain IgA deposit and γδ+ T cells in
paraffin-embedded specimens is a new option for cli-
nicians. The mRNA analyses from duodenal biopsies
could serve as a molecular surrogate for the morpho-
metrical villous: crypt ratio in the future.
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